NSE filing, NSE: REMUS. Summary written from the filing by ALFA Finder's alert engine.
Remus Pharmaceuticals Ltd: key numbers
- Share price
- ₹874.35
- Market cap
- ₹1,030 Cr
- Revenue (annual)
- ₹853.6 Cr
- Net profit (annual)
- ₹36.99 Cr
- P/E (TTM)
- 27.9×Sector 46.1×
- Promoter holding
- 70.95%
- FII holding
- 5.10%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Remus Pharmaceuticals Ltd
All →Remus Pharmaceuticals Annual General Meeting
Remus Pharmaceuticals Limited shareholders approved the migration of equity shares from the NSE Emerge platform to the main boards of NSE and BSE.
Remus Pharmaceuticals Annual General Meeting
Remus Pharmaceuticals held its 11th Annual General Meeting on September 29, 2026. Shareholders discussed financial results, dividend declaration, and director appointments.
Remus Pharmaceuticals Dividend
Remus Pharmaceuticals Limited has fixed September 22, 2026, as the record date for determining shareholder entitlement to a final dividend of Rs. 0.50 per share.
Remus Pharmaceuticals Annual General Meeting
Remus Pharmaceuticals Limited has issued a postal ballot notice seeking shareholder approval for the migration of its equity shares from the NSE Emerge platform to Main Board.
Remus Pharmaceuticals Merger & Restructuring
Remus Pharmaceuticals will incorporate a new subsidiary in the Dominican Republic for pharmaceutical distribution. The company will hold at least 51% of its share capital.
Remus Pharmaceuticals Management Change
Remus Pharmaceuticals Limited has appointed Mr. Ashutosh Naginbhai Valani as a Non-Executive Independent Director, effective September 2, 2026.
Other other announcement announcements
All →Mahindra & Mahindra Financial Services Other Announcement
Mahindra & Mahindra Financial filed its ALM statement as of September 30, 2026, submitted to RBI. It is a periodic regulatory return with no new transaction.
ACME Solar Holdings Other Announcement
ACME Solar filed the CARE Ratings monitoring agency report on its Rs.2,800 crore QIP for the quarter ended 30 September 2026. The report shows no deviation from the offer objects.
eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.